Retatrutide Development Timeline: From Discovery to Phase 3

Introduction

Retatrutide (LY3437943) is one of the most closely watched drug programs in metabolic disease. It took nearly a decade to get from Eli Lilly’s research labs to its current place as a Phase 3 investigational compound. Along the way it reflects a wider shift in incretin-based drugs, from molecules that hit one target to peptides designed to act on several metabolic pathways at once.

Below is a timeline of the key milestones, publications and regulatory decisions in retatrutide’s development, which shows where the drug stands today and what is left before it could reach patients.

Preclinical Discovery and Development (2016-2019)

2016-2018: Molecular Design and Discovery

Retatrutide began in Eli Lilly’s peptide drug research program, where scientists were trying to move past the single-target GLP-1 receptor agonists of the first generation of incretin drugs. The idea rested on growing evidence that hitting several metabolic receptors at once could do more than the sum of the parts.

The key design idea was to add glucagon receptor agonism to the established mix of GLP-1 and GIP receptor agonism. While tirzepatide (then LY3298176) was moving through Lilly’s pipeline as a dual GIP/GLP-1 receptor agonist, the team asked whether a third target, the glucagon receptor, could improve metabolic results further, especially weight loss and liver fat reduction.

This was a hard molecule to design. The team had to build a single peptide that activated three distinct GPCRs in the right balance: enough GCGR activation to drive energy expenditure and fat burning in the liver, but not so much that it swamped the glucose-lowering effects of GLP-1R and GIPR agonism. The molecule also needed half-life extension technology (fatty acid acylation for albumin binding) so it could be given once a week.

After extensive structure-activity relationship studies and repeated refinement, the team chose LY3437943 as the lead candidate. Its potency profile was carefully tuned: high GIPR potency, moderate GLP-1R potency, and lower but still meaningful GCGR potency.

2018-2019: Preclinical Characterization

Animal studies showed that LY3437943 had metabolic effects consistent with action at all three target receptors:

• Weight loss exceeding that observed with single- or dual-agonist comparators
• Glycemic improvement despite the inclusion of GCGR agonism, confirming effective metabolic counterbalancing
• Liver fat reduction that was substantially greater than with GLP-1R agonists alone, consistent with GCGR-mediated hepatic fatty acid oxidation
• Favorable safety signals in toxicology studies sufficient to support progression to human trials

These findings supported the Investigational New Drug (IND) application to the FDA, which opened the way to human trials.

Phase 1 Clinical Development (2019-2021)

2019: First-in-Human Study Initiation

Eli Lilly started the first-in-human Phase 1 trial of retatrutide (then known by its internal code LY3437943) in 2019. This first study (NCT03841630, Singapore, March-July 2019) was a single-ascending-dose study in healthy volunteers; multiple ascending doses were then tested in people with type 2 diabetes in a separate trial (NCT04143802) that started in December 2019.

The Phase 1 program established several key points:

• Safety and tolerability: The drug was tolerated at doses expected to be active, with side effects typical of incretin drugs (mostly gastrointestinal)
• Pharmacokinetics: Measured absorption, terminal half-life (approximately 6 days), and exposure-response relationships that would guide Phase 2 dose selection
• Pharmacodynamics: Showed early signs of glucose-lowering, appetite-reducing and metabolic effects consistent with triple receptor agonism
• Dose range identification: Set the dose range to test in Phase 2 efficacy studies

2020-2021: Phase 1 Expansion and Phase 2 Preparation

The Phase 1 data, together with the preclinical work, gave enough evidence to design the Phase 2 program. Eli Lilly chose a range of doses and escalation schedules for Phase 2, based on the pharmacokinetic and pharmacodynamic relationships seen in Phase 1.

Phase 2 Clinical Development (2021-2023)

2021: Phase 2 Trial Initiation

Two major Phase 2 trials began:

1. Phase 2 Obesity Trial: A randomized, double-blind, placebo-controlled trial testing several retatrutide doses (1 mg, 4 mg, 8 mg and 12 mg) in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity. The primary endpoint was percentage change in body weight at 24 weeks, with 48 weeks as a key secondary endpoint.

2. Phase 2 Type 2 Diabetes Trial: A randomized, double-blind, placebo-controlled trial testing several retatrutide doses in adults with type 2 diabetes not controlled on metformin alone or metformin plus a second drug. The primary endpoint was change in HbA1c at 24 weeks, with treatment continuing to 36 weeks.

Both trials included dose-escalation arms to improve tolerability, because Phase 1 had shown that gradual titration greatly reduced gastrointestinal side effects.

2022: First Peer-Reviewed Publication

A key paper in Cell Metabolism by Coskun and colleagues presented the preclinical work and early clinical data for retatrutide. It was the first detailed public account of the molecule’s receptor pharmacology, including its triple-agonist profile and in vitro potency at each target receptor. The paper laid the scientific groundwork for the molecule and drew wide interest from metabolic researchers.

Why it mattered: For the first time, the wider scientific community could assess the reasoning and early clinical evidence for a triple GIP/GLP-1/glucagon receptor agonist. The idea had been discussed in theory but had never before been shown with a molecule in human clinical development.

2023: Phase 2 Results Published

2023 was a turning point for retatrutide, with Phase 2 results published from both major trials.

June 2023: Phase 2 Obesity Results (New England Journal of Medicine)

Jastreboff and colleagues published the Phase 2 obesity results in the New England Journal of Medicine, one of the world’s most prestigious medical journals. The results were striking:

• 12 mg dose: Approximately 24.2% mean body weight reduction at 48 weeks
• 8 mg dose: Approximately 22.8% mean reduction
• 4 mg dose: Approximately 17.1% mean reduction
• Placebo: Approximately 2.1% reduction

These were among the largest weight losses ever reported for a drug treatment for obesity, beating the published results of both semaglutide 2.4 mg and tirzepatide at their highest doses over similar or longer periods. The paper drew global media coverage and marked retatrutide as a possible next-generation obesity treatment.

Other notable findings: The trial also reported dramatic drops in liver fat (up to approximately 82% relative reduction at the highest dose), better blood pressure and lipids, and side effects typical of incretin drugs.

June 2023: Phase 2 Type 2 Diabetes Results (The Lancet)

Rosenstock and colleagues published the type 2 diabetes Phase 2 results in The Lancet. Key findings included:

• HbA1c reductions of up to approximately 2.0 percentage points, with a high proportion of participants achieving glycemic targets
• Significant weight loss in a diabetes population, where weight reduction is typically more difficult to achieve than in non-diabetic individuals
• Favorable metabolic improvements across multiple parameters

Strong blood sugar control plus large weight loss in people with type 2 diabetes strengthened the case for triple agonism as a treatment approach.

2023: Phase 3 Program Announced

After the positive Phase 2 results, Eli Lilly announced the Phase 3 TRIUMPH program for retatrutide. TRIUMPH was planned as a set of large, pivotal trials across different indications (obesity, type 2 diabetes, MASH) and patient groups, aimed at supporting regulatory submissions for several indications.

Phase 3 Development and the TRIUMPH Program (2023-Present)

2023-2024: TRIUMPH Program Launches

The TRIUMPH Phase 3 program began enrolling participants across several trials. Key features:

• Scale: Thousands of participants across multiple trials and multiple countries
• Indications: Obesity/overweight, type 2 diabetes, and MASH
• Treatment duration: Extended beyond the 48 weeks studied in Phase 2, providing longer-term efficacy and safety data
• Diversity: Broader inclusion criteria compared with Phase 2, including more diverse patient populations, older adults, and patients with comorbidities

Eli Lilly invested heavily in TRIUMPH, a sign of its confidence in retatrutide’s commercial potential and its strategic place alongside the already-approved tirzepatide products.

2024: Additional Preclinical and Mechanistic Publications

In 2024, more papers added to what is known about retatrutide’s pharmacology. Coskun and colleagues published further mechanistic data on its receptor interactions and the metabolic effects of triple agonism, shedding more light on how the three actions work together to produce the clinical results.

Eli Lilly also updated investors and the medical community on the TRIUMPH program, including enrollment status and expected readout dates.

2025: First Phase 3 Results — TRIUMPH-4

2025 brought a major milestone: the first Phase 3 results. In December 2025, Eli Lilly announced the TRIUMPH-4 results in a press release, reporting topline Phase 3 data. As of October 31, 2026 we have not found a peer-reviewed paper reporting TRIUMPH-4. TRIUMPH-4 tested retatrutide in adults with obesity and moderate-to-severe knee osteoarthritis over 68 weeks.

Key results:

• 12 mg dose: -28.7% mean body weight reduction at 68 weeks
• 9 mg dose: -26.4% mean body weight reduction
• Placebo: -2.1% reduction

The TRIUMPH-4 results confirmed and beat the Phase 2 efficacy signals. The trial also found a new safety signal: dysesthesia (abnormal sensations such as tingling, numbness or burning), reported in 8.8% of the 9 mg group and 20.9% of the 12 mg group versus 0.7% with placebo. This signal had not stood out in Phase 2.

The Phase 3 dose escalation protocol was also disclosed (Giblin et al., Diabetes, Obesity and Metabolism, January 2026), describing a 16-week escalation period before maintenance. Reports of the TRIUMPH-1 presentation at ADA 2026 described a 2 mg starting dose raised every 4 weeks, so 12 mg is reached from week 17. That is slower than the 12-week Phase 2 escalation to 12 mg.

2026: Two More Positive Phase 3 Readouts

The first half of 2026 brought two more positive pivotal readouts on top of TRIUMPH-4:

March 19, 2026: TRANSCEND-T2D-1 (Type 2 Diabetes)

Eli Lilly reported positive topline results from TRANSCEND-T2D-1 in a press release on March 19, 2026 (with more detail on the Q1 2026 earnings call on April 30). Across all doses in 537 adults over 40 weeks, retatrutide produced HbA1c reductions of 1.7-2.0 percentage points and weight loss of 11.5-16.8%. Chief Scientific and Product Officer Daniel Skovronsky described the result as blood sugar control comparable to tirzepatide with substantial extra weight loss, which he called clinically meaningful for people with T2D. Dysesthesia rates were clearly lower than in the obesity trials (2.3-4.5% range across doses).

May 21, 2026: TRIUMPH-1 (Pivotal Obesity Trial)

The anchor trial for the obesity indication reported in May:

• 2,339 adults with obesity or overweight + at least one weight-related comorbidity, without diabetes
• 80-week primary endpoint: -28.3% at 12 mg / -25.9% at 9 mg / -19.0% at 4 mg (efficacy estimand); all three doses met primary
• Responder analysis (12 mg): 62.5% achieved ≥25% weight loss; 45.3% achieved ≥30%; 65.3% ended trial with BMI <30
• 104-week extension (BMI ≥35 subgroup): 12 mg arm reached -30.3%
• Dysesthesia at 12 mg: 12.5%, well below TRIUMPH-4’s 20.9% at the same dose
• Discontinuation due to AEs at 12 mg: 11.3%, also lower than TRIUMPH-4’s 18.2%
• Results announced via Eli Lilly press release; peer-reviewed paper published in the New England Journal of Medicine on September 29, 2026

As of October 2026 all five pivotal readouts are in. TRIUMPH-2 (obesity + type 2 diabetes: -20.8% at 12 mg over 80 weeks) and TRIUMPH-3 (severe obesity + cardiovascular disease: -22.6%) reported on July 23, 2026, completing the obesity data package. In the same announcement Eli Lilly said it planned to submit a Biologics License Application to the FDA in Q1 2027 for obesity, obstructive sleep apnea and knee osteoarthritis pain. Lilly now says it plans to file no later than the first quarter of 2027. On October 2, 2026 the FDA ruled that retatrutide is a drug, not a biologic, so the application must be a New Drug Application (NDA); Lilly is challenging the FDA ruling in court and has not said which pathway it will use. In August 2026 Lilly also opened a single-patient expanded access program (NCT07629401) for adults with severe, refractory obesity who cannot join a trial.

Looking Ahead: Remaining Milestones

These projections may change with trial results, regulatory decisions and manufacturing issues.

The Broader Context

Retatrutide’s timeline reflects wider trends in metabolic drug development. The move from single-target GLP-1R agonists (exenatide, liraglutide, semaglutide) to dual-target GIP/GLP-1R agonists (tirzepatide) and now triple-target molecules (retatrutide) shows how fast the field is moving. Each generation has delivered clearly better efficacy by engaging extra metabolic pathways that complement each other.

The speed of retatrutide’s development also shows how mature the incretin drug development model has become. Lessons from earlier drugs in the class, on dose escalation, endpoint choice and regulatory strategy, have made development more efficient. The strong Phase 2 results sped things up further by giving Lilly the confidence to invest in a large Phase 3 program.

Summary

Retatrutide’s development runs from preclinical discovery in the late 2010s through Phase 1 (2019-2021), Phase 2 (2021-2023) and Phase 3 (2023-present). The key Phase 2 papers in NEJM and The Lancet in 2023 marked retatrutide as a potentially transformative metabolic drug and led to the TRIUMPH Phase 3 program. By May 2026, three positive pivotal readouts were in hand: TRIUMPH-4 (Dec 2025, -28.7% at 12 mg in obesity + knee OA), TRANSCEND-T2D-1 (March 19, 2026, HbA1c -1.7 to -2.0 pp and weight -11.5 to -16.8% in T2D), and TRIUMPH-1 (May 21, 2026, -28.3% at 12 mg in 2,339 adults with obesity, no diabetes). TRIUMPH-2 (-20.8% in obesity with type 2 diabetes) and TRIUMPH-3 (-22.6% in severe obesity with cardiovascular disease) reported on July 23, 2026 and completed the regulatory package. Eli Lilly plans to file for approval no later than Q1 2027.